468(top 1%)
papers
25.2K(top 1%)
citations
67(top 1%)
h-index
150(top 0.1%)
g-index
495
all documents
27.2K
doc citations
2.5K
citing journals

Top Articles

#TitleJournalYearCitations
1Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet, The20163,077
2Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet, The20171,728
3Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncology, The20171,388
4EAU Guidelines on Interventional Treatment for UrolithiasisEuropean Urology20161,166
5Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialLancet, The20181,142
6Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine2015907
7Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology2016659
8EAU Guidelines on Diagnosis and Conservative Management of UrolithiasisEuropean Urology2016581
9Current use of PSMA–PET in prostate cancer managementNature Reviews Urology2016469
10Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate CancerEuropean Urology2016456
11Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CTJournal of Nuclear Medicine2018372
12The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging2008355
13Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging2016302
14ctDNA guiding adjuvant immunotherapy in urothelial carcinomaNature2021293
15Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatmentNephrology Dialysis Transplantation2012266
16Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU GuidelinesEuropean Urology2015246
17Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical ProstatectomyJournal of Nuclear Medicine2019238
18Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical ProstatectomyEuropean Urology1999232
19Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialLancet Oncology, The2021225
20Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage LymphadenectomyJournal of Nuclear Medicine2016213
21Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerEuropean Urology2019206
22Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialEuropean Urology2019197
23A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinomaCancer2009196
2499mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate CancerEuropean Urology2019195
25Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate CancerEuropean Urology2015192
2668Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportCancer Imaging2016171
27Preclinical Evaluation and First Patient Application of99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate CancerJournal of Nuclear Medicine2017170
28An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder CancerEuropean Urology2010169
29The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder CancerEuropean Urology2009168
30Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate CancerJournal of Urology2016166
31Prostate-Specific Membrane Antigen Ligands for Imaging and TherapyJournal of Nuclear Medicine2017163
32Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine2020161
33An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancerNature Communications2021159
34Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational StudyJournal of Urology2007149
35Radiation Dosimetry for177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor LesionsJournal of Nuclear Medicine2017144
36Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trialLancet Oncology, The2015137
37EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†European Urology2020132
38Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical ProstatectomyEuropean Urology2018129
39Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMAEuropean Urology2021128
40Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyLancet Oncology, The2021120
41Tract Sizes in Miniaturized Percutaneous Nephrolithotomy: A Systematic Review from the European Association of Urology Urolithiasis Guidelines PanelEuropean Urology2017119
42Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05)European Urology2009117
43Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancerScientific Reports2017117
44Targeting the PI3K/AKT/mTOR Pathway in Bladder CancerMethods in Molecular Biology2018117
4568Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate CancerJournal of Nuclear Medicine2016112
4668Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective StudyJournal of Nuclear Medicine2017111
47Detection of circulating tumor cells in different stages of prostate cancerJournal of Cancer Research and Clinical Oncology2013108
48Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging2013107
49Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging2018107
5068Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET ImagingJournal of Nuclear Medicine2018106